Antigua and Barbuda vs Cyprus: Average non-HDL cholesterol levels
Antigua and Barbuda
3.5
in 2018
Cyprus
3.5
in 2018
Antigua and Barbuda rank
52nd
Cyprus rank
52nd
Average non-HDL cholesterol levels over time
- Antigua and Barbuda
- Cyprus
How they compare
Antigua and Barbuda currently reports 3.5 against 3.5 in Cyprus, a difference of 0.
Across all 39 years both countries report, Cyprus has been ahead every year.
Antigua and Barbuda ranks 52nd and Cyprus ranks 52nd of 191 countries.
Cyprus has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Cyprus | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.23 | 4.2 | 0.97 | Cyprus |
| 1990s | 3.3 | 4.04 | 0.74 | Cyprus |
| 2000s | 3.31 | 3.79 | 0.48 | Cyprus |
| 2010s | 3.43 | 3.62 | 0.1889 | Cyprus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Antigua and Barbuda or Cyprus?
- Antigua and Barbuda, at 3.5 against 3.5 in Cyprus as of 2018.
- What is the difference in average non-hdl cholesterol levels between Antigua and Barbuda and Cyprus?
- 0, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Cyprus?
- 39 years are reported by both, from 1980 to 2018.
- How do Antigua and Barbuda and Cyprus rank globally for average non-hdl cholesterol levels?
- Antigua and Barbuda ranks 52nd and Cyprus ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.